Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 9/20 | 0.52 |
| ▸ | TACR1 | P25103 | 4/20 | 0.46 |
| ▸ | RXRA | P19793 | 3/20 | 0.44 |
| ▸ | RXRB | P28702 | 3/20 | 0.44 |
| ▸ | RXRG | P48443 | 3/20 | 0.44 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392176 | 0.92 | RXRA (0.49) | ICMTTACR1RXRARXRBRXRG | |
| SCHEMBL2391627 | 0.88 | RORB (0.51) | ICMTRORB | |
| SCHEMBL9890734 | 0.86 | FFAR1 (0.49) | ICMTTACR1RXRARXRBRXRG | |
| SCHEMBL2392135 | 0.80 | ICMT (0.44) | ICMTCNR1CNR2 | |
| SCHEMBL9890740 | 0.78 | PTGDR2 (0.46) | ICMTTACR1 | |
| SCHEMBL9892668 | 0.78 | POLQ (0.45) | ICMT | |
| SCHEMBL2395095 | 0.78 | PTGDR2 (0.40) | ICMT | |
| Trifluoroacetic Acid SCHEMBL27625600 | 0.78 | KMT2A (0.47) | TACR1 | |
| SCHEMBL2395669 | 0.78 | ATR (0.39) | ICMT | |
| SCHEMBL9892688 | 0.78 | PTGDR2 (0.53) | ICMTTACR1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885TACR1 2276/4885RXRA 1396/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885TACR1 2276/4885RXRA 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.